11/7/2005

Colgate-Palmolive and Introgen Therapeutics announced a partnership to pursue gene therapy mouthwashes and gels to treat and prevent oral cancers. Colgate-Palmolive is buying $20 million worth of Introgen's stock in a deal the companies hope will eventually develop prescription and over-the-counter products.

Full Story:
NYTimes.com

Related Summaries